Erratum: Paclitaxel poliglumex for ovarian cancer (Expert Opinion on Investigational Drugs (2011) 20(6) (813-21) DOI: 10.1517/13543784.2011.576666);Paclitaxel poliglumex for ovarian cancer

Expert Opinion on Investigational Drugs

Volumn 20, Issue 6, 2011, Pages 813-821

  Galic, Vijaya L ^a   Herzog, Thomas J ^b   Wright, Jason D ^b   Lewin, Sharyn N ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

CT 2103; ovarian cancer; paclitaxel poliglumex

Indexed keywords

CISPLATIN; DOCETAXEL; PACLITAXEL; PACLITAXEL POLIGLUMEX; PLATINUM;

ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG RESEARCH; HUMAN; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; SENSORY NEUROPATHY; THROMBOCYTOPENIA;

EID: 79955827976     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.699224     Document Type: Erratum

References (35)

1. American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society, Atlanta 2010
2. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Betliesda, MD. Available from: http://seer.cancer.gov/csr/1975-2006/ [Last accessed 31 March 2011]
3. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200 (Pubitemid 46606249)
4. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996;23:40-7 (Pubitemid 26391379)
5. Lin Y, Hartman LC, Gunderson HD. Paclitaxel hypersensitivity reactions: prevalence and outcomes. J Clin Oncol 2010;28:abstract e16518
6. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708 (Pubitemid 30365530)
7. Connelly E, Markman M, Kennedy A, et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 1996;62:166-8 (Pubitemid 26274794)
8. Du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-9
9. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-91 (Pubitemid 39585637)
10. von Gruenigen VE, Huang HQ, Gil KM, et al. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer 2009;115:4857-64
11. Shaffer SA, Baker-Lee C, Kennedy J, et al. In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother Pharmacol 2007;59:537-48 (Pubitemid 46122332)
12. Singer JW, Baker B, De Vries P, et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol 2003;519:81-99 (Pubitemid 36577702)
13. Capony F, Rougeot C, Cavailles V, Rochefort H. Estradiol increases the secretion by MCF7 cells of several lysosomal pro-enzymes. Biochem Biophys Res Commun 1990;171:972-8 (Pubitemid 20318045)
14. Ross H, Bonomi P, Langer C, et al. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaive pts with advanced NSCLC and poor performance status (PS2). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24:7039
15. Li C, Newman RA, Wu QP, et al. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol 2000;46:416-22
16. Morgan MA, Darcy KM, Rose PG, et al. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol 2008;110:329-35
17. Li C, Yu DF, Newman RA, et al. Complete regression of well-established tumors using a novel water-soluble poly (L-glutamic acid)-paclitaxel conjugate. Cancer Res 1998;5:2404-9 (Pubitemid 28252701)
18. Langer CJ, O'Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008;3:623-30 (Pubitemid 351787307)
19. Richards DA, Richards P, Bodkin D, et al. Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a Phase II study. Clin Lung Cancer 2005;7:215-20 (Pubitemid 43279872)
20. Paz-Ares L, Ross H, O'Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008;98:1608-13 (Pubitemid 351684693)
21. Lin NU, Parker LM, Come SE, et al. Phase II study of CT-2103 as first-or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs 2007;25:369-75 (Pubitemid 46944845)
22. Beer TM, Ryan C, Alumkal J, et al. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs 2010;21:433-8
23. Dipetrillo T, Milas L, Evans D, et al. Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a Phase I study. Am J Clin Oncol 2006;29:376-9 (Pubitemid 44197542)
24. Herzog T, Barret RJ, Edwards R, Oldham FB. Phase II study of paclitaxel poliglumex (PPX) /carboplatin (C) for 1st line induction and maintenance therapy of stage III/IV ovarian or primary peritoneal carcinoma. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23:5012
25. Todd R, Sludden J, Boddy A, et al. Phase I and pharmacological study of CT-2103, a poly (L-glutamic acid)-paclitaxel conjugate. Proc Am Soc Clin Oncol 2001; 20:abstract 439
26. Mita M, Mita A, Sarantopoulos J, et al. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. Cancer Chemother Pharmacol 2009;64:287-95
27. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-5 (Pubitemid 46606325)
28. Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 2009;114:195-8
29. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106
30. Skubitz KM, Verschraegen CF, Daud A, et al. A phase I study of paclitaxel poliglumex (PPX) in combination with cisplatin (CIS) for patients (pts) with advanced cancer. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23:2089
31. Nemunaitis J, Cunningham C, Senzer N, et al. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest 2005;23:671-6 (Pubitemid 43041714)
32. Sabbatini P, Aghajanian C, Dizon D, et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 2004;22:4523-31 (Pubitemid 41185119)
33. Sabbatini P, Sill MW, O'Malley D, et al. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecol Oncol 2008;111:455-60
34. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323-9
35. Bernard M, Brignone M, Adehossi A, et al. Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: a willingness to pay study. Lung Cancer 2011;72:114-18